To establish AR inhibitor-resistant prostate cancer (IRPC) cell model, we treated LNCaP prostate cancer cells with enzalutamide (ENZ) and EPI-001 (EPI) for 9 days (short-term or ST) and for 33 days (long-term or LT), at concentrations of 10 μM (ENZ) and 8 μM (EPI), respectively, based on IC50 values of cell survival rates in normal FBS culture medium (Fig. 1A), which were used in all drug-treatment experiments. Here, AR is linked to prostate cancer.